Being Alive 1993 Jan 5: 9
The vaccines that we have reported on in the past (gp120 and
gp160 are examples) have worked by increasing HIV antibodies.
With retroviral infections, however, antibodies do not appear
to be enough to completely contain the infection.
At last summer's AIDS conference in Amsterdam, Dr. Jonas Salk,
world renowned developer of the polio vaccine, addressed this
point. Salk conceded that raising antibody levels may be useful
in slowing the progression of HIV. But HIV, he argued, is a
disease of the T-cells. Thus, we need a vaccine that doesn't
just raise antibody levels, but makes T-cells work better in
Now we have word that a new vaccine, geared to a lymphocyte
response, is undergoing a small Phase I trial. This is the
first use in humans of "gene therapy" for HIV. We look forward
to more detailed reports on this new kind of vaccine.